Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Semaglutide improves Alzheimer's symptoms and restores oxytocin levels in mouse and human brain models

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Semaglutide treatment improved cognitive capabilities in APP/PS1 mice, particularly in learning and memory.

  • Behavioral analyses indicated enhanced cognitive functions in mice treated with Semaglutide.
  • Treatment was associated with reduced amyloid plaque deposition in mouse brain tissues.
  • Semaglutide down-regulated glial fibrillary acidic protein (GFAP) and ionized calcium binding adaptor molecule 1 (Iba1) expression.
  • Increased levels of oxytocin (OXT) were observed following Semaglutide treatment.
  • Human Alzheimer's disease organoid models showed reduced amyloid-beta and phosphorylated Tau levels after treatment.
  • The findings suggest potential therapeutic effects of Semaglutide in Alzheimer's disease.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
PubMed

Related papers

Jul '16
Long-term liraglutide treatment does not change amyloid plaque levels in two mouse models of Alzheimer's disease
top 30% journal
cited by 54 papers
journal article
Apr '16
Lack of ABCA7 Protein Speeds Up Amyloid-Beta Production and Alzheimer's Brain Damage
top 5% journal
cited by 139 papers
research support, n.i.h., extramural
Feb '17
How Brain Inflammation and Amyloid Relate to Thinking Problems in a Mouse Model of Alzheimer's Disease
top 10% journal
cited by 86 papers
journal article
Aug '13
Long-term treadmill exercise slows Alzheimer’s-like brain damage in memory areas of genetically modified mice
cited by 119 papers
research support, non-u.s. gov't

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
1 week ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
2 weeks ago7 studies
issue #49
GLP-1 drugs work even without weight loss — and scientists are finally mapping why
3 weeks ago7 studies
issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
4 weeks ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
5 weeks ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
6 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
7 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
8 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
9 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
10 weeks ago8 studies
explore the archive
See more issues from the glp-1 therapies brief